ArticleCancers2021
Gut Microbiota Dynamics during Chemotherapy in Epithelial Ovarian Cancer Patients Are Related to Therapeutic Outcome.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiome alterations and their clinical and biological implications in ovarian cancer: a systematic review.Frontiers in oncology · 2025Pooled it
- Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.Molecular oncology · 2026Article
- The Dual Role of the Gut Microbiota in Cancer Chemoresistance.MicrobiologyOpen · 2026Review
- Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes.Cell reports. Medicine · 2026Article
- Orchestrating the gut microbiota-mitochondrial-immune axis in gynecological diseases: mechanisms and dual-targeting therapeutic strategies.Frontiers in reproductive health · 2026Review
- Critical role of reproductive tract microbiota and derived metabolites in inflammation, tumor immunity, and tumorigenesis of gynecological cancers: a narrative review.Frontiers in immunology · 2026Review
- Gut microbiome-shaped chemotherapy responses across cancer types: mechanisms of resistance, biomarkers, and targeted interventions.Frontiers in immunology · 2026Review
- Diagnostic significance of gut Microbiome dysbiosis and biomarker expression in Egyptians with hepatocellular carcinoma.Scientific reports · 2025Article
- The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies.Cells · 2025Review
- The role of the gut microbiota in chemotherapy response, efficacy and toxicity: a systematic review.NPJ precision oncology · 2025Article
- Gut-Vaginal Microbiome Crosstalk in Ovarian Cancer: Implications for Early Diagnosis.Pathogens (Basel, Switzerland) · 2025Review
- Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.Journal of gynecologic oncology · 2025Article
- Gut microbial and functional signatures in breast cancer: an integrated metagenomic and machine learning approach to non-invasive detection.Frontiers in microbiology · 2025Article
- Understanding dysbiosis and resilience in the human gut microbiome: biomarkers, interventions, and challenges.Frontiers in microbiology · 2025Review
- Gut and oral microbiota in gynecological cancers: interaction, mechanism, and therapeutic value.NPJ biofilms and microbiomes · 2024Review
- Article
- The Gut Microbiome in Aging and Ovarian Cancer.Aging and cancer · 2024Article
- Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study.JHEP reports : innovation in hepatology · 2024Article
- Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications.Microbiome research reports · 2024Review
- Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is one of the most lethal and silent gynecological tumors. Despite appropriate surgery and chemotherapy, relapse occurs in over half of patients with a poor prognosis. Recently, the gut microbiota (GM) was hypothesized to influence the efficacy of anticancer therapies, but no data are available in EOC. Here, by 16S rRNA gene sequencing and inferred metagenomics, we profiled the GM of EOC patients at diagnosis and reconstructed its trajectory along the course of neoadjuvant or adjuvant chemotherapy up to follow-up. Compared to healthy subjects, the GM of EOC patients appeared unbalanced and severely affected by chemotherapy. Strikingly, discriminating patterns were identified in relation to the therapeutic response. Platinum-resistant patients showed a marked temporal reduction in GM diversity and increased instability with loss of health-associated taxa and increased proportions of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.